| Category | Product | Indications | Research Start Date | Current Development Stage | Notes | |
|---|---|---|---|---|---|---|
| Anticancer Drug Immune Checkpoint Inhibitor |
Best-in-class | STT-001 (PD-L1) |
Lung Cancer, Bladder Cancer, etc. | 2014 | Preclinical Studies | |
| STT-002 (PD-1) |
Melanoma, Lung Cancer, Head and Neck Cancer, etc. | 2014 | Preclinical Studies | |||
| First-in-class | STT-003 br (Nelmastobart) | Colorectal Cancer, Lung Cancer, etc. | 2017 | Indication-Specific Phase 1b/2 Clinical Trials |
Initiated in 2017 by STCube & Company and MD Anderson Cancer Center (MDACC). In 2019, the development was contracted to STCube, Inc. |
